us food regulators decide friday whether recommend painkillers linked high risk heart attack stroke
food administration fda advisory panel give verdict hearing evidence three days
painkillers called cox2 inhibitors sold brand names celebrex vioxx
vioxx withdrawn shops last year merck said would consider selling gets fda approval
fda asked decide benefits patients justify increased risks
putting vioxx back shelves likely boost profits merck make easier legal battles people claim injured analysts said
merck voluntarily stopped sales vioxx 30 september move caused firms fourthquarter earnings slide 11bn Â£581m 14bn year earlier
mercks shares tumbled 10 news company set aside millions dollars cover cost vioxxrelated litigation
alarm bells rung research note called approve showed risk heart attack stroke doubled patients taking least 18 months
cox2 inhibitors developed companies including merck pfizer cause users fewer stomach problems painkillers
pfizer still selling celebrex bextra products though investigations suggested may harmful heart
mercks announcement possible reintroduction vioxx caught analysts surprise
mercks head research said withdrew vioxx based information available us time knowing alternative therapies
went say things since changed light new reports
given new information clear cardiovascular risk observed approve makes vioxx unique class similar drugs marketed us mr explained
thursday david graham fdas office safety told advisory panel really doesnt appear need cox2 inhibitors
according calculations presented us senate dr graham november vioxx may linked many 56000 american deaths
facing stem criticism handling vioxx case fda said tuesday create independent body oversee safety drugs already market place
european regulators meanwhile ruled thursday patients heart disease stroke cox2 inhibitors
european medicines agency said doctors cautious giving drugs patients risk factors heart disease

